4DMT Provides Company Update and Anticipated Development Milestones for 2026
4D Molecular Therapeutics, Inc. (FDMT)
Company Research
Source: GlobeNewswire
Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, with 381 patients randomized or approved to randomize as of January 6, 20264D-150 PRISM wet AMD 2-year Phase 2b data expected mid-20264D-150 DME global Phase 3 trial initiation expected Q3 2026; 2-year SPECTRA Phase 1/2 data expected H2 2026Appointed Glenn Sblendorio to Board of Directors, adding deep commercial and operating experience, including in retina therapeuticsCompany to present strategic outlook at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, at 7:30am PT EMERYVILLE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today provided a corporate update and outl
Show less
Read more
Impact Snapshot
Event Time:
FDMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FDMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FDMT alerts
High impacting 4D Molecular Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FDMT
News
- 4D Molecular Therapeutics (NASDAQ:FDMT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.MarketBeat
- Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely [Yahoo! Finance]Yahoo! Finance
- 4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop [Seeking Alpha]Seeking Alpha
- 4D Molecular Therapeutics (NASDAQ:FDMT) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $26.00 price target on the stock.MarketBeat
- 4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease [Yahoo! Finance]Yahoo! Finance
FDMT
Earnings
- 11/10/25 - Beat
FDMT
Sec Filings
- 1/7/26 - Form 4
- 1/7/26 - Form 3
- 1/7/26 - Form 8-K
- FDMT's page on the SEC website